| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 07/23/2002 | US6423717 Nervous system disorders |
| 07/23/2002 | US6423713 Substituted pyrazoles as p38 kinase inhibitors |
| 07/23/2002 | US6423710 Cyclic AMP-specific phosphodiesterase inhibitors |
| 07/23/2002 | US6423708 Aralkyl and aralkylidene heterocyclic lactams and imides |
| 07/23/2002 | US6423699 Contraceptives |
| 07/23/2002 | US6423683 Microdose therapy |
| 07/23/2002 | US6423539 Enhancing immunology response |
| 07/23/2002 | US6423527 Sphingosine-1-phosphate lyase polypeptides, polynucleotides and modulating agents and methods of use therefor |
| 07/23/2002 | US6423507 Detecting enzyme inhibitors; obtain protease, incubate with modulator, monitor adjustment in protease activity |
| 07/23/2002 | US6423327 Treating wrinkles of skin with adenosine |
| 07/23/2002 | US6423320 Inhibitor of immunoglobulin E antibody production |
| 07/23/2002 | CA2365997A1 Novel polypeptide |
| 07/23/2002 | CA2215317C Reduction of adhesions using controlled delivery of active oxygen inhibitors |
| 07/23/2002 | CA2102180C Novel immunosuppressive pyrrolidine/piperidine/azepane-2-carboxylic acid derivatives |
| 07/23/2002 | CA2101556C Growth factor containing matrix for the treatment of cartilage lesions |
| 07/23/2002 | CA2058597C Wound healing compositions containing fibroblast growth factor and ascorbic acid |
| 07/23/2002 | CA2041594C Pyrido[2,3-f][1,4]thiazepines and pyrido[3,2-b][1,5]benzothiazepines |
| 07/23/2002 | CA2040865C Method for preventing, stabilizing or causing regression of atherosclerosis employing a combination of a cholesterol lowering drug and an ace inhibitor |
| 07/22/2002 | CA2368485A1 Combination treatment for depression |
| 07/18/2002 | WO2002056027A2 Regulation of neutral development by daedalos |
| 07/18/2002 | WO2002055728A2 Compositions and methods for regulating receptor clustering |
| 07/18/2002 | WO2002055698A2 Transcriptional mediators of blood vessel development and endothelial differentiation |
| 07/18/2002 | WO2002055693A2 Method for inhibiting the expression of a target gene |
| 07/18/2002 | WO2002055691A1 Gene encoding aip-1/flash promoter and use thereof |
| 07/18/2002 | WO2002055688A2 Histone deacetylase inhibitors in diagnosis and treatment of thyroid neoplasms |
| 07/18/2002 | WO2002055676A2 Method for processing dendritic cells and for activating macrophages with ru 41740 |
| 07/18/2002 | WO2002055663A2 Srebp pathway modulation through targeting hisrs |
| 07/18/2002 | WO2002055547A2 Sfrp and peptide motifs that interact with sfrp and methods of their use |
| 07/18/2002 | WO2002055541A2 Peptides having inhibiting activity on the production of nitric oxide |
| 07/18/2002 | WO2002055525A1 Retinoid agonists |
| 07/18/2002 | WO2002055523A1 Mikanolide derivatives, their preparation and therapeutic uses |
| 07/18/2002 | WO2002055521A1 Purine derivatives as purinergic receptor antagonists |
| 07/18/2002 | WO2002055517A2 4-(hetero)aryl substituted indolinones |
| 07/18/2002 | WO2002055515A1 Chemical derivatives and their use as anti-telomerase agent |
| 07/18/2002 | WO2002055514A2 Substituted benzimidazol-2-ones as vasopressin receptor antagonists and neuropeptide y modulators |
| 07/18/2002 | WO2002055507A1 1-dimercaptoalkylquinazolin-2,4(1h,3h)-diones as matrix metalloproteinase (mmp) inhibitors |
| 07/18/2002 | WO2002055502A1 Pyridine derivatives useful as cyclooxygenase inhibitor |
| 07/18/2002 | WO2002055501A2 N-pyridyl carboxamide derivatives and pharmaceutical compositions containing them |
| 07/18/2002 | WO2002055498A1 Pharmaceutically active piperidine derivatives |
| 07/18/2002 | WO2002055496A1 Aryl piperidine and piperazine derivatives as inducers of ldl-receptor expression |
| 07/18/2002 | WO2002055495A1 Aryl piperidine derivatives as inducers of ldl-receptor expression |
| 07/18/2002 | WO2002055481A1 Prodrugs of excitatory amino acids |
| 07/18/2002 | WO2002055152A2 Composition for inducing islet neogenesis, containing gastrin/cck receptor ligands and egf receptor ligands |
| 07/18/2002 | WO2002055121A1 Drug delivery from stents |
| 07/18/2002 | WO2002055106A2 Combination therapy using receptor tyrosine kinase inhibitors and angiogenesis inhibitors |
| 07/18/2002 | WO2002055103A1 Tumor vaccines |
| 07/18/2002 | WO2002055099A2 Modulation of pericyte proliferation using bpi protein products or bpi inhibitors |
| 07/18/2002 | WO2002055098A2 Latency associated peptide for providing latency to pharmaceutically active proteins |
| 07/18/2002 | WO2002055094A1 Injectable hypo-osmolar solution |
| 07/18/2002 | WO2002055088A1 Remedies for bone marrow suppression and infectious diseases and white blood cell count elevating agents |
| 07/18/2002 | WO2002055086A2 Hormone replacement therapy method and its administration form |
| 07/18/2002 | WO2002055084A1 PYRROLO[2,3-d]PYRIMIDINE AND THEIR USE AS PURINERGIC RECEPTOR ANTAGONISTS |
| 07/18/2002 | WO2002055083A1 TRIAZOLO[4,5-d] PYRIMIDINE DERIVATIVES AND THEIR USE AS PURINERGIC RECEPTOR ANTAGONISTS |
| 07/18/2002 | WO2002055079A2 Aza-and polyaza-naphthalenyl carboxamides useful as hiv integrase inhibitors |
| 07/18/2002 | WO2002055072A1 Regulation of lipids and/or bone density and compositions therefor |
| 07/18/2002 | WO2002055070A1 Dihydrofuran cyclic tanshintones used in treating hyperammonemia and hepatic encephalopathy |
| 07/18/2002 | WO2002055065A2 Use of an ltb4 antagonist for the treatment and/or prevention of diseases caused by increased expression of mucin genes |
| 07/18/2002 | WO2002055049A1 Cosmetic and/or pharmaceutical preparations |
| 07/18/2002 | WO2002055048A1 Cosmetic and/or pharmaceutical preparations |
| 07/18/2002 | WO2002055022A2 Active metabolite of antifungal compound |
| 07/18/2002 | WO2002055021A2 Glycopolymers and free radical polymerization methods |
| 07/18/2002 | WO2002055016A2 INHIBITION OF NF-λB BY TRITERPENE COMPOSITIONS |
| 07/18/2002 | WO2002055014A2 Therapeutic chroman compounds |
| 07/18/2002 | WO2002055012A2 Therapeutic heterocyclic compounds |
| 07/18/2002 | WO2002054851A2 Inhibition of pathological angiogenesis in vivo |
| 07/18/2002 | WO2002048349A8 Polypeptide capable of binding to heparin |
| 07/18/2002 | WO2002041834A3 Atorvastatin hemi-calcium form vii |
| 07/18/2002 | WO2002041831A3 Inositol derivatives for increasing chloride secretion and inhibiting inflammation |
| 07/18/2002 | WO2002034202A3 Multi-component antioxidant compounds, pharmaceutical compositions containing same and their use for reducing or preventing oxidative stress |
| 07/18/2002 | WO2002029088A3 Highly expressible genes |
| 07/18/2002 | WO2002028418B1 Methods of modulating apoptosis by administration of relaxin agonists or antagonists |
| 07/18/2002 | WO2002024661A3 New n, n'-disubstituted benzimidazolone derivatives with affinity at the serotonin and dopamine receptors |
| 07/18/2002 | WO2002022558A3 2-amino-2-alkyl-3 heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors |
| 07/18/2002 | WO2002022557A3 2-amino-2-alkyl-4 heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors |
| 07/18/2002 | WO2002016358A3 Quinuclidine-substituted aryl moieties for treatment of disease (nicotinic acetylcholine receptor ligands) |
| 07/18/2002 | WO2002016355A3 Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic) acetylcholine receptor ligands |
| 07/18/2002 | WO2002013758A3 System for regulating in vivo the expression of a transgene by conditional inhibition |
| 07/18/2002 | WO2002012249A3 Substituted pyrrole compounds and their use as spla2 inhibitors |
| 07/18/2002 | WO2002011704A3 Use of aryl-substituted 1,1-diphosphonates for the treatment of bone diseases |
| 07/18/2002 | WO2002009713A3 Selective pde 2 inhibitors, used as medicaments for improving cognition |
| 07/18/2002 | WO2002009680A3 Pharmacologically active substance for treating cardiovascular disorders |
| 07/18/2002 | WO2002008198A3 Novel imidazolidinones as ns3-serine protease inhibitors of hepatitis c virus |
| 07/18/2002 | WO2002007722A3 Valproic acid and derivatives thereof as histone deacetylase inhibitors |
| 07/18/2002 | WO2002006242A3 5-substituted 2-aryl-4-pyrimidinones |
| 07/18/2002 | WO2002004522A3 Bifunctional molecules and vectors complexed therewith for targeted gene delivery |
| 07/18/2002 | WO2002002633A3 Transporters and ion channels |
| 07/18/2002 | WO2002002556A3 AZA-BRIDGED-BICYCLIC AMINO ACID DERIVATIVES AS α4 INTEGRIN ANTAGONISTS |
| 07/18/2002 | WO2002002143A3 Enhancement of antibody-cytokine fusion protein mediated immune responses by combined treatment with immunocytokine uptake enhancing agents |
| 07/18/2002 | WO2001096299A3 Indole derivatives and their use as 15-lipoxygenase inhibitors |
| 07/18/2002 | WO2001094951A3 Inhibitors of c-reactive protein induced inflammation |
| 07/18/2002 | WO2001094391A3 Intracellular signaling proteins |
| 07/18/2002 | WO2001094345A3 Derivatives of 2,3,6,7,12,12a-hexahydropyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione |
| 07/18/2002 | WO2001090328A3 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| 07/18/2002 | WO2001090103A3 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives and their use as protein kinase modulators |
| 07/18/2002 | WO2001088134A3 Novel human lipocalin homologs and polynucleotides encoding the same |
| 07/18/2002 | WO2001087980A3 Isolated human g-protein coupled receptors, nucleic acid molecules encoding human gpcr proteins, and uses thereof |
| 07/18/2002 | WO2001085790A3 Mammalian cytokine receptor subunit proteins, related reagents and methods |
| 07/18/2002 | WO2001083749A3 Gene and sequence variation associated with sensing carbohydrate compounds and other sweeteners |
| 07/18/2002 | WO2001083525A3 Modified peptides, comprising an fc domain, as therapeutic agents |
| 07/18/2002 | WO2001081590A3 Protein phosphatases |